CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Arizona Tribune - CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM ET in New York City. CASI will also host one-on-one meetings with investors at the conference.

Text size:

A live webcast of the fireside chat will be available on the CASI Pharmaceuticals website at www.casipharmaceuticals.com under the "Investors" tab. A replay of the webcast will be available for 90 days after the live event.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) and plans to initiate the study in third quarter of 2025.

More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT:

Ingrid Choong, PhD
650-619-6115
[email protected]

SOURCE: CASI Pharmaceuticals

View the original press release on ACCESS Newswire

T.Perez--AT

RBGPF	0.44%	63.75	$
CMSC	-0.04%	22.82	$
RYCEF	-2.68%	14.9	$
RELX	-0.59%	35.8	$
GSK	-5.97%	51.4	$
BP	0.96%	46.8	$
NGG	-1.71%	85.98	$
AZN	-0.8%	185.2	$
BTI	-1.78%	57.45	$
RIO	-2.07%	96.49	$
CMSD	-0.61%	23.06	$
BCE	-1.03%	23.26	$
JRI	-0.55%	12.74	$
BCC	-4.57%	79	$
VOD	-0.98%	15.34	$

Arizona Tribune - CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Featured

New Zealand mosque killer loses bid to overturn convictions

Australian Jewish group warned of 'terrorist attack' before Bondi shooting: inquiry

Powell's decision to stay on at Fed ignites new Trump insult

Romanian behind 'swatting' attacks in US gets four years in prison